Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study

Table 6 Adjudicated cardiovascular events and non-cardiovascular death (safety analysis population)

Patients with at least one event, n	Aleglitazar 150 μg (n = 149)	Pioglitazone 45 mg (n = 152)
MACE
Cardiovascular death	2	2*
Non-fatal myocardial infarction	0	1
Non-fatal stroke	0	1*
Non-cardiovascular death	1	1
Congestive heart failure
Non-fatal heart failure (hospitalized)	2	0
Non-fatal heart failure (non-hospitalized)	2	0

*Non-fatal stroke and cardiovascular death occurred in the same patient, thus total number of patients experiencing at least one MACE event was two in aleglitazar group and three in pioglitazone group. The same patient has also experienced a myocardial infarction, as judged by the investigator (not included in the above summary), but insufficient information was provided to the Clinical Events Committee to conclusively adjudicate this event as myocardial infarction or unstable angina (cardiac enzymes data was not available). MACE = major adverse cardiovascular events.

ISSN: 1471-2369